Abstract:Head and neck cancer (HNC) affects over 890,000 people annually worldwide and has a mortality rate of 50%. Aside from poor survival, HNC pain impairs eating, drinking, and talking in patients, severely reducing quality of life. Different pain phenotype in patients (allodynia, hyperalgesia, and spontaneous pain) results from a combination of anatomical, histopathological, and molecular differences between cancers. Poor pathologic features (e.g., perineural invasion, lymph node metastasis) are associated with increased pain. The use of syngeneic/immunocompetent animal models, as well as a new mouse model of perineural invasion, provides novel insights into the pathobiology of HNC pain. Glial and immune modulation of the tumor microenvironment affect not only cancer progression but also pain signaling. For example, Schwann cells promote cancer cell proliferation, migration, and secretion of nociceptive mediators, whereas neutrophils are implicated in sex differences in pain in animal models of HNC. Emerging evidence supports the existence of a functional loop of cross-activation between the tumor microenvironment and peripheral nerves, mediated by a molecular exchange of bioactive contents (pronociceptive and protumorigenic) via paracrine and autocrine signaling. Brain-derived neurotrophic factor, tumor necrosis factor α, legumain, cathepsin S, and A disintegrin and metalloprotease 17 expressed in the HNC microenvironment have recently been shown to promote HNC pain, further highlighting the importance of proinflammatory cytokines, neurotrophic factors, and proteases in mediating HNC-associated pain. Pronociceptive mediators, together with nerve injury, cause nociceptor hypersensitivity. Oncogenic, pronociceptive mediators packaged in cancer cell–derived exosomes also induce nociception in mice. In addition to increased production of pronociceptive mediators, HNC is accompanied by a dampened endogenous antinociception system (e.g., downregulation of resolvins and μ-opioid receptor expression). Resolvin treatment or gene delivery of μ-opioid receptors provides pain relief in preclinical HNC models. Collectively, recent studies suggest that pain and HNC progression share converging mechanisms that can be targeted for cancer treatment and pain management.

Progress in the Study of Peripheral Mechanism of Hone Cancer Pain

Progress in the basic research on neurobiological mechanisms of cancer pain]

Research advances in mechanisms and management of bone cancer pain

Advances in cancer pain from bone metastasis

Molecular mechanisms of cancer pain

Schwann Cell-Derived CXCL2 Contributes to Cancer Pain by Modulating Macrophage Infiltration in a Mouse Breast Cancer Model

The Potential Therapeutic Targets to Bone Pain Induced by Cancer Metastasis

STUDIES ON THE EXCITABILITY OF THE PRIMARY AFFERENT SENSORY NEURONS IN A RAT BONE CANCER PAIN MODEL

Research Progress of Treatment for Advanced Cancer Pain

[Research progress on analgesic mechanism of acupuncture for cancer pain]

Neurophysiological mechanisms of cancer-induced bone pain

Researeh Progress for Tumor Ache

Advancement of Neuropathic Pain Mechanisms in Pancreatic Cancer

Advances in Head and Neck Cancer Pain

Differences in electrophysiological properties of functionally identified nociceptive sensory neurons in an animal model of cancer-induced bone pain

Cancer–nerve interplay in cancer progression and cancer-induced bone pain

Pain Behavior and the Expression of Phosphorylated Camp Response Element Binding Protein and Brain-Derived Neurotrophic Factor in Dorsal Horn of Spinal Cord in a Mouse Model of Bone Cancer Pain

Recent advances in understanding and managing cancer pain

Research progress on the endothelin axis and cancer pain

Establishment of a Murine Pancreatic Cancer Pain Model and Microarray Analysis of Pain-Associated Genes in the Spinal Cord Dorsal Horn

[Express] Roles of TNF-α and IL-6 in regulating bone cancer pain via TRPA1 signal pathway and beneficial effects of inhibition of neuro-inflammation and TRPA1.